Literature DB >> 9794144

Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins.

J Pavía1, M L de Ceballos, F Sanchez de la Cuesta.   

Abstract

Senile dementia is one of the most important health problems in developed countries. The main disease causing dementia is Alzheimer's disease that is characterized by the progressive deterioration of the cholinergic system, beta-amyloid production and deposition, and neurofibrillary tangle formation. Most of the reviewed data, along with data from experiments performed in our laboratory, suggest that there are no changes in the number of muscarinic receptors between Alzheimer and control brains, although the receptors expressed in Alzheimer's disease brains can be anomalous in their function. The muscarinic receptor-G-protein interaction also seems to be impaired in Alzheimer's disease compared with control brains, as well as the G-protein system, with an important decrease in the function of the Gq/11, the most important G-protein stimulating phosphoinositide hydrolysis in human brain; in addition, the second messenger system is also impaired, with a decrease in the synthesis of phosphoinositides and in the number of IP3 receptors. Muscarinic cholinergic receptors are also linked to beta-amyloid production, stimulation of the M1 subtype with agonists results in the processing of the beta-amyloid precursor protein to non-amyloidogenic products and administration of a fraction of the beta-amyloid (beta-amyloid 25-35) to rats, results in a decrease in the number of muscarinic receptors in brain. M1 agonists also decrease the phosphorylation of tau proteins, playing again a modulatory role in the pathogenesis of Alzheimer's disease. The existence of a link between beta-amyloid and tau proteins also has been reported; treatment of hippocampal neurones with beta-amyloid, or the 25-35 residue fragment, resulted in an increase in tau protein phosphorylation. The particular contribution of muscarinic receptors, beta-amyloid and tau proteins in the pathogenesis of Alzheimer's disease remains still unclear. Probably Alzheimer's disease could be due to a progressive degeneration in the relationship between the three components covered in this review.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794144     DOI: 10.1111/j.1472-8206.1998.tb00975.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  Protein τ-mediated effects on rat hippocampal choline transporters CHT1 and τ-amyloid β interactions.

Authors:  Zdena Kristofikova; Daniela Ripova; Katerina Hegnerová; Jana Sirova; Jiri Homola
Journal:  Neurochem Res       Date:  2013-07-04       Impact factor: 3.996

2.  Theory of Visual Attention (TVA) applied to mice in the 5-choice serial reaction time task.

Authors:  C M Fitzpatrick; M Caballero-Puntiverio; U Gether; T Habekost; C Bundesen; S Vangkilde; D P D Woldbye; J T Andreasen; A Petersen
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

3.  Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease.

Authors:  Alvaro O Ardiles; Cheril C Tapia-Rojas; Madhuchhanda Mandal; Frédéric Alexandre; Alfredo Kirkwood; Nibaldo C Inestrosa; Adrian G Palacios
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

4.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Authors:  Abraham Fisher; Rachel Brandeis; Rachel Haring Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Hagar Sonego; Itzhak Marcovitch; Zipora Pittel
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

5.  Pharmacological models in Alzheimer's disease research.

Authors:  C Gilles; S Ertlé
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

6.  Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling.

Authors:  Tamara L Kinzer-Ursem; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2007-01-12       Impact factor: 4.475

7.  Alzheimer's disease care and management: role of information technology.

Authors:  Hanuman Thota; Allam Appa Rao; Kiran Kumar Reddi; Sivaprasad Akula; Suresh Babu Changalasetty; Gedela Srinubabu
Journal:  Bioinformation       Date:  2007-11-03

Review 8.  Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.

Authors:  Gabriela Dumitrita Stanciu; Andrei Luca; Razvan Nicolae Rusu; Veronica Bild; Sorin Ioan Beschea Chiriac; Carmen Solcan; Walther Bild; Daniela Carmen Ababei
Journal:  Biomolecules       Date:  2019-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.